Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 47.7% in October

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 108,100 shares, a drop of 47.7% from the October 15th total of 206,700 shares. Approximately 27.4% of the company’s stock are sold short. Based on an average trading volume of 905,000 shares, the days-to-cover ratio is currently 0.1 days.

Avalon GloboCare Trading Down 1.3 %

Avalon GloboCare stock opened at $3.12 on Thursday. Avalon GloboCare has a 1-year low of $2.11 and a 1-year high of $21.60. The company has a market capitalization of $3.34 million, a P/E ratio of -0.16 and a beta of 0.31. The firm’s fifty day simple moving average is $3.37 and its 200-day simple moving average is $4.91.

Avalon GloboCare (NASDAQ:ALBT) last posted its quarterly earnings results on Monday, August 19th. The company reported ($2.85) earnings per share for the quarter. The business had revenue of $0.33 million for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.